An expert panel calls the requirement for tuberculosis testing before prescribing IL-17 and IL-23 biologics for psoriasis an ...

Patients with psoriasis who receive antibiotics may be more likely to discontinue their biologic therapy, a new study suggests. 1 In this French cohort study, the effect increased with multiple ...

Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...

Psoriasis can affect the fingers, knuckles, nails, palms, and soles. Here’s what this psoriasis looks like and how to relieve symptoms like itch.

The blogger Howard Chang explores the latest advancements bringing hope for a psoriasis cure, some of which were presented at a community event.

There are a few ingredients that can help treat dry patches. “I advise patients to look for products that contain hyaluronic ...

Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...

The sNDA was supported by data from a 4 week MUSE study and a long-term open-label study in children aged 2 to 5 years.

Johnson & Johnson (JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM ESTCompany ParticipantsCandice Long - Worldwide ...

Treatment with envudeucitinib was safe and effective through 52 weeks among patients with with moderate to severe plaque psoriasis.

Biologic therapy use among patients with psoriatic disease was associated with a lower risk for malignancy compared with topical therapy use.